26Apr
26Apr
OmniLife Health Launches First and Only Clinical Workflow Automation Tool For Pediatric Organ Intake Management
In the U.S., more than 1,900 children are awaiting an organ transplant. Tragically, many of these children will die before they receive the gift of life, despite the fact plenty of donor organs are available. To help transplant centers improve organ intake and save more children, OmniLife Health, a leader in clinical workflow automation, has expanded its award-winning FlowHawk platform to pediatric care. Called FlowHawk for Kids, this end-to-end solution automates and digitizes the transplant journey, from patient referral and...
26Apr
EcoSoul Home Raises $10 Million, Plans To Expand To Newer Markets: Rahul Singh Exclusive | CNBC-TV18
EcoSoul Home Inc is seeing a seismic shift in consumer interest towards sustainable products. It has raised $10 million in a series A round which it plans to expand to Europe, UK and Asian markets. In an exclusive conversation with CNBC-TV18, Rahul Singh, co-founder of Ecosoul, said that he is excited to see the strong adoption of our products in the US market and is looking forward to expand the firm's product range in potential international markets. Watch now >>
25Apr
ARVO LIVE: eSight Go: Smart glasses for low vision enhancement
Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement. "Our current product is in our booth, but what we're excited about is a product we will be launching at the end of 2023. It is the eSight Go, smart glasses for low vision enhancement, and in essence, the product does a similar functionality...
20Apr
Xylyx Bio Matrikynes Exhibits Clinical Anti-aging, Barrier Repair Efficacy
Xylyx Bio, a regenerative medicine company focused on technologies for organ and tissue repair, has released a white paper from an independent clinical study showing its Matrikynes ingredient (INCI: Not Provided), based on matrikines, is safe and highly effective for anti-aging and other topical skin care applications. Effects included reversing common signs of skin damage and aging, including the reduction of lines and wrinkles. Matrikynes is comprised of a mixture of natural extracellular matrix-derived peptides, i.e., matrikines. The intrinsic bioactivity...
20Apr
EcoSoul Home Inc. announces USD 10 million – Series A round led by Accel and Singh Capital Partners
EcoSoul Home Inc., a category-leading start-up in the eco-friendly home essentials products space, has raised USD 10 million to wrap up its Series A round. This round is led by Accel and saw the participation of Singh Capital Partners. Over the past year, the company has seen tremendous growth in the US market. It has established itself as a leading player across key e-commerce platforms and retail banners in multiple product categories. Read more >>
19Apr
Pyramid Biosciences and GeneQuantum Healthcare Announce Preclinical Data for GQ1010, a Potential Best-In-Class TROP2-Targeted Antibody Drug Conjugate, at the 2023 AACR Annual Meeting
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, and its partner GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, announced data at the American Association for Cancer Research (AACR) Annual Meeting 2023 highlighting the preclinical efficacy and safety profile of GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), across several in vitro and in vivo models. The poster presentation highlights...
14Apr
Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, today announced that it has entered into an exclusive license agreement with GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, to develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan). GQ1010 has shown a highly differentiated preclinical profile, and is anticipated to enter...
13Apr
DetraPel Announces the Re-Brand of its Industrial Pillar to Impermea Materials, an Advanced Materials Company Manufacturing PFAS-Free, Fluorine-Free and Plastic Alternative Solutions
Formally known as DetraPel, Impermea Materials unveils its new brand as it expands its offerings across food & packaging, textiles, automotive, and more as regulatory and consumer demands increase for PFAS-free and plastic-free goods. Read more >>
11Apr